Evidence map›Paper›PMID 35918295›Full record

Trial reportRespirology (Carlton, Vic.)2022

Reversal of collateral ventilation using endoscopic polymer foam in COPD patients undergoing endoscopic lung volume reduction with endobronchial valves: A controlled parallel group trial.

Alvin J Ing, Anand Jayapadman, Woo-Veen Kim, Chelsea Ly, Kevin Ho-Shon, Paul Lilburn, Alan Carew, Benjamin J H Ng, Tajalli Saghaie, Jonathan P Williamson

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Respirology (Carlton, Vic.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. ERJ Advances: interventional bronchoscopy.The European respiratory journal · 2024
    Article
  5. Surgical and bronchoscopic pulmonary function-improving procedures in lung emphysema.European respiratory review : an official journal of the European Respiratory Society · 2023
    Review
  6. Review
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Alvin J IngFaculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.ORCID 0000-0002-6391-020X
Anand JayapadmanFaculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.
Woo-Veen KimFaculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.
Chelsea LyFaculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.
Kevin Ho-ShonFaculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.
Paul LilburnMQ Health, Macquarie University Hospital, North Ryde, New South Wales, Australia.ORCID 0000-0001-7449-3854
Alan CarewDepartment of Thoracic Medicine, Prince Charles Hospital, Chermside, Queensland, Australia.ORCID 0000-0002-3212-381X
Benjamin J H NgRespiratory Medicine, MQ Health, Macquarie University Hospital, Sydney, New South Wales, Australia.
Tajalli SaghaieFaculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.
Jonathan P WilliamsonFaculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.ORCID 0000-0003-4957-3961
Macquarie University · AUPrince Charles Hospital · AUUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveWe have previously described reversal of collateral ventilation (CV) in a severe chronic obstructive pulmonary disease (COPD) patient with endoscopic polymer foam (EPF), prior to endoscopic lung volume reduction (ELVR) with valves. The aim of this study was to investigate the efficacy of this in a larger cohort and compare outcomes with a similar cohort with no CV.

methodsPatients with severe COPD, with the left upper lobe (LUL) targeted for ELVR, were assessed for CV with high resolution computed tomography (HRCT). If fissure completeness was >95% they were enrolled as controls for valves alone (endobronchial valve control group [EBV-CTRL]). If fissure completeness was 80%-95%, defects were mapped to the corresponding segment, where EPF was instilled following confirmation of CV with CHARTIS. EBVs were inserted 1 month afterwards.

resultsFourteen patients were enrolled into both arms. After 6 months, there were significant improvements in both groups in forced expiratory volume in 1 s (FEV1; +19.7% EPF vs. +27.7% EBV-CTRL, p < 0.05); residual volume (RV; -16.2% EPF vs. -20.1% EBV-CTRL, p = NS); SGRQ (-15.1 EPF vs. -16.6 EBV-CTRL p = NS) and 6 min walk (+25.8% EPF [77.2 m] vs. +28.4% [82.3 m] EBV-CTRL p = NS). Patients with fissural defects mapped to the lingula had better outcomes than those mapped to other segments (FEV1 +22.9% vs. +16.3% p < 0.05). There were no serious adverse reactions to EPF.

conclusionEPF successfully reverses CV in severe COPD patients with a left oblique fissure that is 80%-95% complete. Following EBV, outcomes are similar to patients with complete fissures undergoing ELVR with EBV alone. EPF therapy to reverse CV potentially increases the number of COPD patients suitable for ELVR with minimal adverse reactions.

Indexed as

Pulmonary Disease, Chronic ObstructivePulmonary EmphysemaBronchoscopyForced Expiratory VolumeHumansPneumonectomyPolymersRespiratory Aerosols and DropletsTreatment OutcomePolymersbronchoscopy and interventional techniqueschronic obstructive pulmonary diseasecollateral ventilationCOPDendobronchial valveendoscopic lung volume reductionpolymer foam

Identifiers

PMID35918295
OpenAlexW4289524398

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.